David Meek

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
David Meek
CEO of Ipsen
Assumed office
Preceded byMarc de Garidel
Personal details
David Meek Jr

(1963-09-12) 12 September 1963 (age 55)
EducationBachelor of Arts, University of Cincinnati (2000)

David Meek (born September 12, 1963) is an American businessman. He has over 25 years of international experience in the pharmaceutical industry. He held various global executive positions in major pharmaceutical and biotechnology companies.[1]

In July 2016, the Board of Directors of Ipsen (Euronext: IPN), a French pharmaceutical company, appointed David Meek as Chief Executive Officer.

Early life[edit]

David Meek holds a Bachelor of Arts (B.A.) in Business Administration and Management from the University of Cincinnati.


In January 2001, he began his career as National Field Sales Director CNS and Primary Care in Janssen Biotech, Pharmaceutical Companies of Johnson & Johnson (until December 2004 based in Titusville, NJ).

He later joined Novartis Pharmaceuticals ($NVS), where he ran the company's respiratory and dermatology franchise in Switzerland (January 2005 – June 2007) before heading up operations in Canada (CEO & President, June 2007 - January 2010) [2] and later running its oncology biz in Europe (January 2010 - August 2012).

He’s not only been in the pharmaceutical industry, however, and before joining Baxter he was the COO of Endocyte ($ECYT) from August 2012 to July 2014, based in Indianapolis.[3][4][5]

He later joined Baxter International Inc. as Head of Oncology division (July 2014 - June 2015, based in Cambridge, Massachusetts).

He was Executive Vice-President and President of the oncology division of Baxalta Inc., which was recently acquired by Shire (July 2015 – July 2016 based in Cambridge, MA).[6][7][8]

In July 2016, the Board of Directors of Ipsen (Euronext: IPN; ADR: IPSEY), has appointed David Meek as Chief Executive Officer, effective July 18, 2016. David Meek will be based at Ipsen’s headquarters in Boulogne-Billancourt, a suburb of Paris.[9][10][11][12][13]

On June 7, 2017 the Shareholders’ Meeting approved the appointment of David Meek, Margaret A. Liu and Carol Stuckley as Directors for a term of four years.[14]

On July 10, 2017 less than a year into the job, Davis Meek laid out a strategy to acquire cancer, neurological and rare-disease treatments. So Ipsen aims for sales to rise to more than 2.5 billion euros in 2020 from almost 1.7 billion euros last year.[15]


  1. ^ "David Meek biography". Bloomberg. Retrieved 2016-08-16.
  2. ^ "David Meek, CEO Novartis Canada". Canada's research. Retrieved 2008-10-16.
  4. ^ "David Meek leaves Novartis to join Endocyte as first chief commercial officer". PMlive. Retrieved 2012-07-30.
  5. ^ "Endocyte appoints Novartis vet David Meek as chief commercial officer". Center watch. Retrieved 2012-07-29.
  6. ^ "Baxalta's oncology chief builds out company's third leg". Medical marketing and media - Larry Dobrow. Retrieved 2015-12-18.
  7. ^ "Baxalta: The fastest-growing oncology drug 'startup' in Kendall Square". Boston business journal. Retrieved 2015-12-11.
  8. ^ "David Meek, president of oncology division of Baxalta". Baxalta. Retrieved 2015-07-11.
  9. ^ "Ipsen Names David Meek CEO". Nasdaq. Retrieved 2016-07-11.
  10. ^ "David Meek appointed CEO Ipsen". Pharma Forum - Richard Staines. Retrieved 2016-08-16.
  11. ^ "After Baxalta-Shire merger, David Meek lands CEO job at leaderless Ipsen". Fiercebiotech - Ben Adams. Retrieved 2016-07-11.
  12. ^ "David Meek appointed as Chief Executive Officer of Ipsen". Business Wire. Retrieved 2016-08-16.
  13. ^ "Ex-Baxalta exec David Meek takes Paris-based helm for Ipsen". Endpoints news - John Carroll. Retrieved 2016-07-11.
  14. ^ "Combined-Shareholders-Meeting-of-IPSEN" (PDF). Ipsen.
  15. ^ "Combined-Shareholders-Meeting-of-IPSEN says small is beautiful when scouting for new medicines". Bloomberg.

External links[edit]

Business positions
Preceded by
Marc de Garidel
CEO of Ipsen
Succeeded by